Effect of omega-3 supplementation on semen profile (semen volume, sperm count, sperm motility, sperm morphology) in infertile men

Investigating the effect of omega-3 supplement treatment on the spermogram disorder of infertile men, including the recovery rate of seminal fluid volume, sperm count, sperm motility rate, and sperm shape.

A controlled, parallel-group, single-blind, randomized, phase 3 clinical trial on 58 patients. Randomized permutation block method was used for randomization.

After fully explaining the research plan and obtaining informed consent, infertile men with spermogram disorders referring to the treatment clinics of Ghaem Hospital in Mashhad are included in the study. After examining the exclusion criteria, the patients are divided into two groups. In the control group, in addition to the necessary and routine treatments, a placebo is useddaily for 3 months. In the intervention group, in addition to the routine treatment, oral omega-3 treatment with a dose of 1000 mg per day is performed for 3 months. Three months after the start of the study, new spermograms will be performed in both groups and will be compared and analyzed.

Inclusion criteria: Infertile men aged 20-45 years not taking Omega 3 supplements in the last 6 months Exclusion criteria: The presence of underlying disease disrupting spermogram Smoking and alcohol consumption Occupations related to high temperatures

In the control group, in addition to the necessary and routine treatments to improve the spermogram disorder, a placebo is used daily for 3 months. In the intervention group, in addition to the routine treatment, oral omega-3 treatment with a dose of 1000 mg per day is performed for 3 months.

The volume of seminal fluid, the number and concentration of sperm, the amount of sperm movement and the amount of normal morphology of sperm at the beginning and 3 months after consuming omega-3.

The samples will be determined by random block method with blocks of 4 and using random numbers table of Random Allocation Software. Blocking and allocation sequence for concealment will be done by a person not involved in the research. Allocation ratio of samples will be 1:1 and they will be placed in two groups. Then, based on the obtained blocks and according to the allocation sequence, the drugs will be given to the patients. The method is that we determine the number of blocks according to the sample size. Each block is numbered and is used for 4 patients. For example, if block number 2 is selected and its treatment group is ABAB, the first patient will receive treatment A, the second patient will receive treatment B, the third patient will receive treatment A, and the fourth patient will receive treatment B.

After obtaining consent, the patients are included in the study and then they are divided into two control and intervention groups. Because the patients of the control group receive placebo, the intervention and control groups will not be distinguishable. Medicine and placebo are completely similar to each other in terms of shape, color and route of administration.